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the population was female (56.0%) with a mean Charlson comorbidity score of 0.43. 
Mean age was 21.6 years with 55.7% under the age of 18. The most common OP pro-
cedures were diagnostic (10.3%) while valve and septa operations (15.6%) and heart 
catheterization (11.9%) were the most frequent IP procedures. Mean LOS was 10.4 
days. Congestive heart failure (CHF) (RR 1.31, 95% CI 1.12, 1.51) fluid and electrolyte 
disorders (ED) (RR 1.68 CI1.46, 5.74), and ventricular septal defects (RR 1.33, CI1.09, 
1.62) diagnoses were associated with longer IP stays. 5.0% of patients admitted 
expired in the hospital and 8.5% were readmitted within 30 days. CHF (OR 2.26 CI 
1.10, 5.12), ED (OR 3.51 CI 1.49, 8.62), and cardiac dysrhythmias (OR 2.63 CI 1.22, 8.62), 
were associated with increased mortality. Only CHF (OR 2.64 CI 1.46, 4.68) was associ-
ated with increased readmissions. CONCLUSIONS: While EA patients are typically 
treated in the OP setting hospital utilization is high when IP services are required.
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OBJECTIVES: Thyroid cancer (TC) constitutes ~1% of all diagnosed cancers. DTC is 
the most common type of TC, accounting for about 95% of all cases. Most patients 
with DTC respond well to surgery and/or radioiodine therapy (I-131). However, 
< 5% of patients become refractory to I-131. Disease burden and healthcare costs 
associated with this orphan disease have not been well described. METHODS: This 
retrospective cohort analysis combined data from the Humana and OptumInsight 
Claims databases from Apr2005-Jun2014. Patients age > = 18 years were defined as 
having RAI-R DTC if they received a tyrosine-kinase inhibitor (TKI) and had > = 2 
diagnoses of thyroid cancer (ICD-9 code 193.xx) on or prior to the index date (first 
TKI use). Patients were excluded if no continuous medical/pharmacy coverage in 
the 6-months pre and post-index. Descriptive results included mean all-cause and 
thyroid-related total healthcare cost & utilization (inpatient, outpatient and phar-
macy), and were assessed 6 months post-index then converted to annual estimates. 
Results were reported for both the individual and combined datasets. RESULTS: A 
total of 116 patients ( Humana= 36; Optum= 80 patients) were identified. Mean age 
was 60 years and 45.7% were female. The average time from diagnosis to TKI use 
was 754 days. The most common TKIs were sorafenib (41.4%), sunitinib (26.7%), 
and vandetanib (14.7%), and 31.9% of patients used > = 2 TKIs. The average number 
of outpatient and ER visits were 43.4 and 1.2 for all-cause, and 22.2 and 0.3 for 
thyroid-related, respectively. Rates of hospitalization were 25.0% and 11.2% for all- 
and thyroid-related causes, with a mean stay of 7.8 and 5.1days, respectively. The 
average number of all-cause and thyroid-related prescriptions were 40.9 and 15.7, 
respectively. Total all- and thyroid-related annual healthcare costs were $127,935 
and $97,344, respectively. CONCLUSIONS: RAI-R DTC is a rare disease, with high dis-
ease burden as shown through high rates of healthcare utilization and annual cost.
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OBJECTIVES: We evaluated the economic burden of treating skeletal-related events 
(SREs), including pathologic fractures (PF), spinal cord compression (SCC), radia-
tion to bone (RB) and bone surgery (BS), in prostate cancer (PC) patients with bone 
metastasis (BM). METHODS: PC patients with a BM diagnosis between 01/01/2005 
and 03/01/2012 were identified in the Truven Health Analytics databases. Propensity 
score was used to match BM patients with SREs to those without. A pseudo-SRE date 
was assigned to the control group that was parallel to the SRE date of the matched 
SRE patients. We compared the total and per member per month (PMPM) costs of 
patients between two groups for the 6-month post-SRE/ pseudo-SRE date. RESULTS: 
We identified 4,975 PC men with BM where 910 patients with SREs were 1:1 matched 
to the non-SRE patients. For those men with at least one SRE, 95.8% received RB; 
17.6% had PF; 12% received BS; and 10.4% had SCC. On average, the total 6-month 
costs of treating patients with SREs were $47,724, compared to $24,729 for the 
matched control cohort (p< 0.001). The mean PMPM cost for non-SRE patients was 
$4,122. The largest proportion of differences in costs between two groups incurred 
in the first month after the SRE-index date ($16,564 vs. $4,636, p< 0.001), and were 
mostly attributable to outpatient visits (65.7%, p< 0.001) and inpatient hospitaliza-
tion (29.1%, p< 0.001). CONCLUSIONS: For PC patients with BM, costs of treating 
those with SREs are significantly higher than comparable patients without SREs. 
Most of costs were incurred in the first month after the occurrence of SREs, but 
while costs decreased thereafter, they remained significantly higher for patients 
with SRE in subsequent months.
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OBJECTIVES: Pancreatic cancer is considered one of the toughest cancers to treat, 
with extremely poor prognosis. The objective of this research was to conduct a 
systematic review of epidemiology and the burden of pancreatic cancer. METHODS: 
A systematic literature search for epidemiology and the burden of disease studies 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar and 
Cochrane. Data was collected for the study type, methods, country and key find-
ings. Extracted study data included pancreatic cancer incidence, complications, 
cant difference in inpatient costs (p< 0.01) between the 2 groups. CONCLUSIONS: 
The economic burden of patients using new bio-surgical hemostatic materials was 
considerable. While a number of factors affected inpatient costs, patients using ORC 
were associated with lower total inpatient expenditure.
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OBJECTIVES: The objective of this literature review was to explore the existing evi-
dences regarding cost-effectiveness of allogeneic hematopoietic stem cell transplan-
tation (AHSCT) in hematologic cancers (HCs). METHODS: A systematic literature 
review was performed using the PICO method: Population consisted of patients suf-
fering from HCs; Intervention and Comparators were AHSCT compared to different 
types of AHSCT or standard therapies and Outcomes were incremental cost-utility 
ratios (ICURs) and/or incremental cost-effectiveness ratios (ICERs). The literature 
search was performed with the NHS EED filters using electronic databases from 
1948 until August 2014. RESULTS: The literature review allowed retrieving 5,805 
studies of which 13 fulfilled the eligibility criteria. Three studies included economic 
analysis on acute myeloid leukemia (AML), two on acute lymphoid leukemia (ALL), 
five on acute leukemias, three on chronic myeloid leukemia (CML) and one on 
myelodysplastic syndromes. Nine were cost-effectiveness analyses and four were 
cost-utility analyses. Five studies used a Markov model. The largest proportion of the 
studies compared AHSCT to standard chemotherapy (SC) (n= 5), followed by imatinib 
(n= 2) and various other comparators (n= 6). The time horizon varied from 1 year to 
lifetime. All studies used a health care system perspective. In AML and ALL, ICERs 
ranged from dominant to (2014US)$154,597/LYG compared to SC. In Philadelphia-
positive (Ph+) CML, ICERs for imatinib ranged from dominant to (2014US)$127,013/
QALY compared to AHSCT. CONCLUSIONS: Most of analyzed studies suggest that 
AHSCT is cost-effective in AML and ALL compared to SC, but not in Ph+CML when 
compared to imatinib, despite a wide cost-effectiveness ratios range. This is con-
sistent with current clinical practice in Ph+CML, where tyrosine kinase inhibitors, 
like imatinib, have replaced AHSCT for first-line therapy. Despite the high level of 
heterogeneity among selected studies, this review provides a comprehensive over-
view of the cost-effectiveness of AHSCT in HCs and could serve in the realization 
of future economic evaluations.
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OBJECTIVES: A literature search revealed no prior study on the direct medical 
costs for gynecologic cancer, including uterine, cervical, ovarian and other gyneco-
logic cancers. The study objective was to estimate the direct healthcare costs of 
gynecologic cancers among community-dwelling U.S. residents from an all-payer 
perspective. METHODS: A retrospective cross-sectional analysis was conducted 
using the 2007-2011 Medical Expenditure Panel Survey (MEPS) databases for patients 
with gynecologic cancers. Direct healthcare costs in the U.S. were estimated using 
gynecologic cancer-related expenditures by source of payment and service type. 
Generalized linear models with a gamma distribution and a log link were used 
to estimate adjusted mean expenditures based on patients’ characteristics. Costs 
were adjusted to 2011 U.S. dollars using the Consumer Price Index-Medical (CPI-
M). RESULTS: A total of 282 patients (average annual weighted N= 568,245) were 
identified with gynecologic cancer diagnoses across the study years. The estimated 
annual direct healthcare cost attributable to gynecologic cancers was $3.86 billion. 
The estimated average annual direct healthcare cost per patient was $6,794 (stand-
ard error [SE]= $1,269). Medicare accounted for most of the total expenditures (44%), 
followed by private insurance (38%). Over half (56%) of the total costs were generated 
by inpatient hospitalizations. The annual predicted costs (SE) per patient were $5,887 
($1,059) in patients with one type of gynecologic cancer and $13,129 ($6,573) in 
patients with two different types of gynecologic cancers. The annual predicted cost 
(SE) per patient with ovarian cancer was $15,693 ($7,912), which was higher than that 
for uterine ($9,590±$3,636) and cervical cancers ($7,935±$3,668). CONCLUSIONS: 
Gynecologic cancers place a considerable economic burden on society. The major-
ity of expenditures was driven inpatient hospitalizations and Medicare accounted 
for the largest portion of payments. This study can provide better understanding 
of the economic burden of gynecologic cancers and contribute to future policy on 
gynecologic cancer prevention and control programs.
PCN50
HosPital UtilizatioN iN PatieNts WitH eBsteiN’s aNomaly
Craver C.W.1, Belk K.2
1MedAssets, Inc., Huntersville, NC, USA, 2MedAssets, Mooresville, NC, USA
OBJECTIVES: Ebstein’s anomaly (EA) is a rare congenital heart disorder affecting the 
tricuspid valve in approximately one out of every 200,000 live births. Treatment for 
EA is focused on reducing symptoms and avoiding disease progression to complica-
tions like heart failure or arrhythmia. The objective of this analysis is to examine 
hospital-based utilization in patients with EA. METHODS: A retrospective cross-
sectional study was conducted on EA discharges in the MedAssets health system 
data for inpatient (IP) and outpatient (OP) visits between January 2009 and December 
2014. Age and gender, hospital characteristics, clinical comorbidities and meas-
ures of utilization including length of stay (LOS) and readmissions were described. 
Multivariable regression was used to identify significant drivers of hospital-based 
utilization. RESULTS: Hospital utilization occurred primarily in the OP setting 
(81.0%) in teaching facilities (88.3%) with 300 or more beds (78.1%). More than half 
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for Chinese journals, were searched through to Dec. 31th, 2014. RESULTS: In 2010, 
incidence and mortality of lung cancer in China are 46.08/105 and 37.00/105. DALYs 
(disability adjusted life years) and economic burden of lung cancer are extremely 
high in both Beijing and Shanghai. DALYs of lung cancer are 42219.38 and 91962.18 
in Beijing and Shanghai respectively. And average hospitalization expenditures per 
lung cancer inpatient are ¥38595.00 and ¥50026.65, among which average drug costs 
per inpatient are as high as ¥18139.65(46.97%) and ¥30356.00(60.68%). CONCLUSIONS: 
Lung cancer has made Chinese patients incur great loss in both DALYs and money, 
which is a conspicuous reminder to policy makers to pay more attention to manage-
ment of the raging disease. And early prevention and screening of lung cancer should 
be priorities to slow increasing speed of disease burden.
PCN57
aCCess of oral CHemotHeraPy for NoN-small Cell lUNg CaNCer 
(NsClC) iN first liNe treatmeNt iN Brazil: imPaCt to tHe PatterNs of 
Care aNd Cost of illNess
Piedade A.1, Goes L.2, Minowa E.1, Castro A.P.3, Alves A.F.1
1Evidências - Kantar Health, Campinas, Brazil, 2Evidências Credibilidade Científica, São Paulo, 
Brazil, 3Evidências, Campinas, Brazil
OBJECTIVES: Previous real world data from 2013 showed the patterns of care of first-
line NSCLC treatment in the Brazilian supplementary health system: carboplatin 
with pemetrexed (29.7%), bevacizumab containing regimens (20.8%) and oral chemo-
therapy (6%). The same study reported the average cost of management of this 
patients as 19.001,79USD. However, treatment patterns and cost of illness may have 
changed after enacting of a federal law (number 12880/2013) that has established the 
mandatory coverage of oral chemotherapy by the supplementary system. Therefore, 
the aim of this analysis was to evaluate the impact of oral chemotherapy incorpo-
ration in the patterns of care and cost of illness of first-line NSCLC treatment in 
Brazil. METHODS: All metastatic NSCLC patients receiving first-line treatment dur-
ing 2014 were eligible and retrieved from the private market administrative claims 
database (Evidencias- Kantar Health database). Patterns of care were evaluated and 
compared before and after introduction of law 12880/2013. The cost of illness was 
calculated by a bottom-up approach. Exams, fees, and associated drugs reported 
were also considered for costing and values were derived from Tables Simpro and 
CBHPM. Exchange rate used was 1.00USD = 2.20BRL. RESULTS: We studied 110 
patients with first-line NSCLC and found 19 different chemotherapy regimens. We 
observed few changes in the patterns of care: carboplatin with premetrexed is still 
the most used (32,7%), followed now by carboplatin with paclitaxel (19,1%) and 
bevacizumab containing regimen (16,4%). Oral chemotherapy represented 9,1% of 
the regimens. Costs of schemes ranged from 4,963.75USD to 52,374.55USD and the 
calculated average cost of management of one patient is 23,725.76USD. Additionally, 
there was a significant increase in the number PET CT required, from 28% in 2013 to 
48% in 2014. CONCLUSIONS: We observed a low impact of oral chemotherapy incor-
poration in the patterns of care and cost of illness of first-line NSCLC treatment.
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OBJECTIVES: Tyrosine kinase inhibitors (TKIs) represent the standard therapy to 
manage chronic myeloid leukemia (CML) and have resulted in a greatly reduced 
mortality rate. However, up to 40% of patients experience first-line failure, with 
many patients experiencing second-line. This analysis examined healthcare uti-
lization and costs for CML patients that switched to a third-line TKI after having 
failed both first- and second-line TKI therapy. METHODS: Patients with a CML diag-
nosis during 1/1/2010-7/31/2014 and a subsequent claim data for a first-, second-, 
and third-line TKI were identified from the Truven Health MarketScan® Research 
Databases. Inclusion criteria: ≥18 years, continuous enrollment from 3 months 
prior to 6 months post first TKI treatment, no stem cell transplant, and switched to 
second- and third-line TKIs. Healthcare utilization and costs were calculated on a 
per-month basis between (1) initiation of first-line TKI until the switch to second-
line TKI and (2) between second-line TKI initiation until the switch to third-line TKI. 
Nonparamtreic tests were used to test for differences. RESULTS: 137 patients were 
identified (male=532%; female=46.8%; mean age=57.34 years). Average duration of 
first-line TKI therapy was 301.62 days and 269.36.9 days for second-line. Although 
there were large differences among patients, overall, the number of monthly out-
patient visits was higher (p<.05) during second-line therapy (mean=10.51; SD=12.32) 
relative to first-line therapy (mean=9.48; SD=11.37). There were no significant dif-
ferences in monthly emergency room visits or hospitalizations. Healthcare costs 
were higher (p<.05) during second-line therapy than first-line therapy averaging 
$19,764 vs. $13,283 respectively. CONCLUSIONS: Experiencing treatment failure and 
switching to a second- and third-line TKI represents disruption in therapy and was 
associated with substantial healthcare utilization and economic burden for patients 
with CML. This was especially more costly and burdensome for patients who failed 
the second-line TKI therapy, as multiple TKI switches   were associated with a greater 
number of outpatient visits and higher healthcare costs.
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OBJECTIVES: HER2 positive breast cancer management can be costly when a mono-
clonal antibody treatment like trastuzumab is used. This is particularly problematic 
in middle-income countries with a national health insurance system , which have 
mortality, available treatment options, as well as healthcare resource utilization 
and medical costs associated with pancreatic cancer. Critical analyses of study 
quality and data gaps were analyzed at the country level. RESULTS: A total of 328 
studies were identified based on the keywords. Of these, 32 studies met the inclusion 
criteria. Studies indicate that pancreatic cancer has an extremely poor prognosis: 
for all stages combined, the 1- and 5-year relative survival rates are 25% and 6%, 
respectively. Pancreatic cancer is the fourth most common cause of cancer-related 
deaths in the United States and the eighth worldwide. More than 50% of patients 
come to clinical attention with metastatic disease, and an additional 30%–40% pre-
sent with locally advanced tumors. Current treatments include surgery and pallia-
tive chemotherapy such as gemicitabine and gemcitabine/erlotinib combination. 
Recently nab-paxclitacel was approved based on a 1.8 month improvement in the 
overall survival. CONCLUSIONS: This systematic review shows that patients with 
pancreatic cancer have a very low survival rate. There is an urgent need for new 
treatments for these patients.
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OBJECTIVES: Cutaneous T-Cell Lymphoma (CTCL) is a rare and serious cancer with 
significant deterioration in patient quality of life. The objective of this research was 
to conduct a systematic review of epidemiology and the burden of CTCL. METHODS: 
A systematic literature search for epidemiology and the burden of disease studies 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar and 
Cochrane. Data was collected for the study type, methods, country and key findings. 
Extracted study data included: CTCL incidence, complications, mortality, available 
treatment options, as well as healthcare resource utilization and medical costs 
associated with CTCL. Critical analyses of study quality and data gaps were analyzed 
at the country level. RESULTS: A total of 50 studies were identified based on the 
keywords. Of these, 14 studies met the inclusion criteria. Studies indicate that CTCL 
is a group of disorders characterized by localization of neoplastic T lymphocytes 
to the skin. Annual overall incidence of CTCL was 6.4 per million persons between 
1973 and 2002. CTCLs accounted for 71%, with Mycosis fungoides (MF) and Sézary 
syndrome (SS) representing the most common sub-types (54 % of all CTCLs). CTCL 
is associated with a significant symptom burden. Pruritus appears to be one of 
the most prominent and disturbing symptoms. All aspects of QOL are affected in 
CTCL. Two new treatments were approved for CTCL during 2009-2012 (US), however, 
the unmet need remains high. CONCLUSIONS: This systematic review shows that 
patients with CTCL have a very poor prognosis and serious deterioration in quality 
of life. There is an urgent need for new treatments for these patients.
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OBJECTIVES: Data on the association of disability with advanced melanoma are 
limited. This exploratory retrospective cohort study determined rates, timing, 
and costs of STD and LTD in adult patients with newly diagnosed advanced mela-
noma. METHODS: The sample was derived from US administrative claims data-
bases (Truven Health MarketScan®). Disability costs were adjusted to 70% of an 
estimated $30/hour replaced wage. RESULTS: Between April 1, 2011, and December 
31, 2012, 1,052 patients were diagnosed with advanced melanoma. Of these, 109 
patients (mean age, 51.1 years; 92.7% employed full-time) had data eligibility, among 
whom 94 and 95 had STD or LTD eligibility, respectively. Fourteen and 9 patients 
went on STD or LTD, respectively; 2 went on both. Mean time between diagnosis and 
STD or LTD was 115.0 days and 221.8 days, respectively. Mean number of STD and 
LTD days were 67.2 and 105.7, respectively. Seven STD and 6 LTD patients received 
melanoma-specific treatment. Mean time between treatment initiation and STD 
or LTD was 59.4 and 202.5 days, respectively. Mean number of on-treatment days 
(time from treatment initiation until the run-out date, defined by the supply for oral/
subcutaneous products or expected clinical benefit for infused products) was 16.4 
during STD and 25.1 during LTD. Among STD and LTD patients with a return-to-work 
record (n= 14 and n= 5, respectively), mean time to work re-entry was 85.6 and 76.4 
days. Mean costs to employers were similar for STD and LTD ($1,302/patient/month 
vs $1,349/patient/month). CONCLUSIONS: This study provides preliminary esti-
mates of the course of work disability and associated costs in patients with newly 
diagnosed advanced melanoma. Melanoma often affects younger patients thus it 
is important to refine the estimated burden associated with lost work productivity 
in a larger sample with long-term follow up. Future research must also explore the 
impact of recently introduced melanoma therapies on this burden.
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OBJECTIVES: Lung cancer has now become NO.1 disease of all cancers in both inci-
dence and mortality in China. Since lung cancer imposes great disease and eco-
nomic burden on patients in China, lots of studies have investigated national status 
of disease burden of lung cancer. However, few studies pay attention to disease bur-
den of lung cancer in China’s super big cities, such as Beijing &Shanghai. Our study 
aims to review lung cancer’s burden in Beijing and Shanghai to inform policy mak-
ing. METHODS: A comprehensive literature review of disease burden of lung cancer 
in Beijing Shanghai was conducted. “CNKI” and “Wanfang data”, the biggest databases 
